Shots:

• The P-III REACH3 study involves the safety & efficacy of ruxolitinib vs BAT in patients with steroid-refractory chronic GVHD
• The study showed improvements in 1EPs i.e ORR (49.7% vs 25.6%) & BOR (76.4% vs 60.4%) @24wks. & also showed the improvements in 2EPs i.e patients achieved longer FFS than BAT- m-FFS (not reached vs. 5.7mos.); improvements in self-reported symptoms (24.2% vs 11.0%)- no new safety signals were observed
• The new subgroup analysis showed higher ORR for Jakavi-treated patients regardless of individual organs involved at baseline. Regulatory submissions are currently ongoing for acute & chronic GvHD outside the US

  Ref: Novartis | Image: Novartis